Ray Dalio’s Madrigal Pharmaceuticals MDGL Stock Holding History

Ray Dalio’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,920	Closed	-$2.05M	–	1108
2026 Q1	$2.05M	Sell	3,920 -15,298	-80%	-$7.31M	0.01%	653
2025 Q4	$11.2M	Sell	19,218 -8,567	-31%	-$4.38M	0.04%	327
2025 Q3	$12.7M	Buy	+27,785	New	+$10.4M	0.05%	285

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Ray Dalio's MDGL Position: Q2 2026 in Review

Ray Dalio sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2026, closing a stake of 3,920 shares — an estimated $2.05M sold.

Ray Dalio first reported a position in MDGL in Q3 2025 and held it in 3 quarters. The position peaked at $12.7M in Q3 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Ray Dalio reported no remaining Madrigal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Ray Dalio sold 3,920 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $2.05M.
Ray Dalio first reported a position in Madrigal Pharmaceuticals in Q3 2025 and held it in 3 quarters.
Ray Dalio's Madrigal Pharmaceuticals position peaked at $12.7M in Q3 2025.
414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.